Stockscreener 앱 받기
10.84
1.45%
-0.16
시간 외 거래:
10.84
전일 마감가:
$11.00
열려 있는:
$10.7
하루 거래량:
9,667
Relative Volume:
2.08
시가총액:
$91.80M
수익:
$70,100
순이익/손실:
$-9.16M
주가수익비율:
-9.9204
EPS:
-1.0927
순현금흐름:
$-6.67M
1주 성능:
+3.73%
1개월 성능:
+48.49%
6개월 성능:
-15.13%
1년 성능:
-7.74%
1일 변동 폭
$10.59
$11.37
1주일 범위
$10.59
$13.40
52주 변동 폭
$7.08
$18.40
Exozymes Inc Stock (EXOZ) Company Profile
명칭
Exozymes Inc
전화
(626) - 415 - 1488
주소
750 ROYAL OAKS DR, MONROVIA
Compare EXOZ vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXOZ
Exozymes Inc
|
10.84 | 93.16M | 70,100 | -9.16M | -6.67M | -1.0927 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Exozymes Inc 주식(EXOZ)의 최신 뉴스
Insider Sell: Tyler Korman Sells 1,500 Shares of EXoZymes Inc (EXOZ) - GuruFocus
eXoZymes Advances Toward Planned Securities Offering Preparation - TipRanks
eXoZymes (EXOZ) files investor presentation tied to proposed securities offering - Stock Titan
Exozymes (EXOZ) CSO logs small April open-market stock sales - Stock Titan
eXoZymes CCO discusses NCTx spinout on podcast - Investing.com
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast - ACCESS Newswire
Surprises Report: What are eXoZymes Incs recent SEC filings showing2026 Support & Resistance & Verified Technical Trade Signals - baoquankhu1.vn
Exozymes Incannounces common stock offeringSEC filing - marketscreener.com
eXoZymes (NASDAQ: EXOZ) files prospectus for common stock offering with affiliated underwriter - Stock Titan
Pullback Watch: Is eXoZymes Inc backed by strong institutional buyingPortfolio Update Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
EXOZYMES (EXOZ) CCO awarded 146,437 options and 62,759 restricted shares - Stock Titan
EXOZYMES (NASDAQ: EXOZ) Chief Commercial Officer files initial Form 3 - Stock Titan
Insider Trends: Can eXoZymes Inc sustain earnings growthMarket Sentiment Review & Growth Oriented Trading Recommendations - baoquankhu1.vn
Latest EXOZ ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
EXOZ Technical Analysis & ETF Price Forecast - Intellectia AI
EXOZYMES (NASDAQ: EXOZ) CCO receives 8,887-share stock grant - Stock Titan
EXOZYMES (EXOZ) VP awarded 3,999 common shares as stock grant - Stock Titan
[Form 4] EXOZYMES INC. Insider Trading Activity - Stock Titan
Exozymes (EXOZ) CSO receives 5,332-share stock award - Stock Titan
Bond Watch: Is eXoZymes Inc a speculative investment2026 Price Swings & Detailed Earnings Play Strategies - baoquankhu1.vn
Does eXoZymes Inc stock have upside surprise potential2026 Fundamental Recap & Weekly Market Pulse Updates - baoquankhu1.vn
EXOZ PE Ratio & Valuation, Is EXOZ Overvalued - Intellectia AI
Nasdaq Moves: Is eXoZymes Inc forming a bullish divergenceShare Buyback & High Accuracy Buy Signal Tips - baoquankhu1.vn
EXoZymes Inc (EXOZ) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
eXoZymes Provides Fourth Quarter and Full Year 2025 Update - Bitget
EXOZ: NCT achieved kilo-scale production and tech transfer, with a financing round in progress - TradingView — Track All Markets
eXoZymes Inc's Capital Raise Delays and NCT Timeline Shifts Highlight Strategic Contradictions - Bitget
eXoZymes Q4 Earnings Call Highlights - MarketBeat
EXOZ: Pilot-scale NCT production achieved; financing round underway to support 2027 commercial launch - TradingView
Earnings call transcript: eXoZymes Q4 2025 results show strategic focus - Investing.com
eXoZymes ends 2025 with $3.04M cash as financing round nears - Stock Titan
eXoZymes Updates Investor Presentation for NCTx Business - TipRanks
eXoZymes (NASDAQ: EXOZ) files updated NCTx investor presentation - Stock Titan
eXoZymes Q4 2025 Earnings Call Transcript - MarketBeat
eXoZymes (NASDAQ: EXOZ) outlines exozyme platform and NCT plans - Stock Titan
EXoZymes, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
EXoZymes, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Institution Moves: Can eXoZymes Inc sustain earnings growth2026 Geopolitical Influence & Technical Pattern Recognition Alerts - baoquankhu1.vn
Why Use Living Cells? NLR Is Making Chemicals With Enzymes Alone - National Laboratory of the Rockies (NLR) (.gov)
eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026 - ACCESS Newswire
EXOZ Price Today: eXoZymes Inc. Stock Price, Quote & Chart - MEXC Exchange
Whale Trades: Can eXoZymes Inc sustain earnings growthRate Hike & High Accuracy Investment Entry Signals - baoquankhu1.vn
eXoZymes to release 2025 results before March 31 investor call - Stock Titan
eXoZymes (NASDAQ:EXOZ) Shares Up 2.4%What's Next? - MarketBeat
Momentum Shift: Is eXoZymes Inc forming a bullish divergenceForecast Cut & Reliable Price Action Trade Plans - baoquankhu1.vn
If You Invested $1,000 in eXoZymes Inc (EXOZ) - Stock Titan
Growth Recap: Whats the beta of eXoZymes Inc stock2026 Top Decliners & Long-Term Safe Return Strategies - baoquankhu1.vn
Aug PostEarnings: What is eXoZymes Incs market positionEarnings Risk Summary & Fast Moving Trade Plans - baoquankhu1.vn
Whale Trades: Will eXoZymes Inc benefit from seasonality2026 Analyst Calls & Technical Pattern Based Signals - baoquankhu1.vn
Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability - ACCESS Newswire
Successful pilot scale run with Cayman Chemical validates eXoZymes' technology and scalability - SynBioBeta
Exozymes Inc (EXOZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):